Adalimumab

• 

  Subject Areas on Research

  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. 
  • A Case Report of Acute Cellular Rejection Following Intestinal Transplantation Managed With Adalimumab. 
  • Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. 
  • Adalimumab for the treatment of psoriasis. 
  • Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials. 
  • Adalimumab in Patients with Active Noninfectious Uveitis. 
  • Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. 
  • Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. 
  • Association of Disorganization of Retinal Inner Layers With Visual Acuity In Eyes With Uveitic Cystoid Macular Edema. 
  • Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. 
  • Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study. 
  • Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. 
  • Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. 
  • High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. 
  • Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. 
  • Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. 
  • Life threatening liver disease during treatment with monoclonal antibodies. 
  • Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. 
  • Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Pediatric neuro-Behçet's disease responsive to adalimumab. 
  • Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. 
  • Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. 
  • Profile of adalimumab and its potential in the treatment of uveitis. 
  • Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab. 
  • Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. 
  • Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III. 
  • Should all patients undergoing treatment with biologic agents be screened annually for latent tuberculosis infection with an interferon gamma release assay? 
  • Spondyloarthritis in a patient with unilateral buttock pain and history of Crohn disease. 
  • The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. 
  • Treatment Strategies for Deficiency of Adenosine Deaminase 2.